Orange Book product · Brand (NDA)
EXELON
RIVASTIGMINE TARTRATE
At a glance
Apr 21, 2000
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Apr 21, 2000
26 yr 7 mo ago
Today
Pharmaceutical detail
Active ingredient
RIVASTIGMINE TARTRATE
Strength
EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
NDA 020823
Product number
004
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2000EXELONBrand (NDA)
NDA 021025 · NOVARTIS
- 2017RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 207797 · CHARTWELL RX
- 2017RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 203844 · CADILA PHARMS LTD
- 2016RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 204572 · AUROBINDO PHARMA
- 2015RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 090879 · ORBION PHARMS
- 2014RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 203148 · MACLEODS PHARMS LTD
- 2013RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 091072 · APOTEX INC
- 2012RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 091689 · ALEMBIC PHARMS LTD
- 2008RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 077129 · WATSON LABS
- 2007RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 077130 · DR REDDYS LABS INC
- 2007RIVASTIGMINE TARTRATEGeneric (ANDA)
ANDA 077131 · SUN PHARM
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
